| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Biological Chemistry, Harvard Medical School, Boston, Massachusetts 02115
Abstract
The designation "activated macrophage" was originally introduced to describe the state of macrophages that have an enhanced ability to phagocytize microorganisms and exert antimicrobial activity. This effect was found to be dependent upon particular infections and involves the participation of lymphocytes (1, 2). "Activation" has a specific immunologic basis, but its expression is nonspecific. Mackaness has written lucidly about activated macrophages and has referred readers back to the concepts of Lurie in tuberculosis, and further to the fons et origo of thinking in this context, i.e., to concepts of Metchnikoff (3). The latter's oft quoted phrase regarding a "perfecting of the phagocytic and digestive powers of the leukocytes" might well be, broadly speaking, synonymous with "activation." Once it was determined that macrophages taken from animals at some appropriate time after infection, for example, with Listerria or Bacillus Calmette-Guérin2 (BCG), were superior to control cells with respect to their antimicrobial powers, it was natural for inquiry to be made into the differences between such cells and normal (control) cells, in terms of their morphology, cellular chemistry, and biochemical attributes.
Footnotes
1 This work was supported by United States Public Health Service Grant No. AI-03260 from the National Institute of Allergy and Infectious Diseases.
2 Abbreviations used in this paper: BCG, Bacillus Calmette-Guérin; PPD, purified protein derivative of Mycobacterium tuberculosis; am, antimicrobial; at, antitumor.
This article has been cited by other articles:
|
|
 |
|
  K. Takeda, N. Yamaguchi, H. Akiba, Y. Kojima, Y. Hayakawa, J. E. Tanner, T. J. Sayers, N. Seki, K. Okumura, H. Yagita, et al. Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy J. Exp. Med., February 17, 2004; 199(4): 437 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. O. Kim, K. Ono, and J. Han Apoptosis by pan-caspase inhibitors in lipopolysaccharide-activated macrophages Am J Physiol Lung Cell Mol Physiol, November 1, 2001; 281(5): L1095 - L1105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Sampaio, M. C. C. Sousa-e-Silva, P. Borelli, R. Curi, and Y. Cury Crotalus durissus terrificus snake venom regulates macrophage metabolism and function J. Leukoc. Biol., October 1, 2001; 70(4): 551 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Sung Ouk Kim and Jiahuai Han Pan-caspase inhibitor zVAD enhances cell death in RAW246.7 macrophages Innate Immunity, August 1, 2001; 7(4): 292 - 296. [Abstract] [PDF]
|
|
|
|
 |
|
 T. A. Ignatowski and J. M. Bidlack Differential kappa -Opioid Receptor Expression on Mouse Lymphocytes at Varying Stages of Maturation and on Mouse Macrophages after Selective Elicitation J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 863 - 870. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. P. Perera and T. A. Waldmann Activation of human monocytes induces differential resistance to apoptosis with rapid down regulation of caspase-8/FLICE PNAS, November 24, 1998; 95(24): 14308 - 14313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Brisseau, S. Grinstein, D. J. Hackam, T. Nordström, M. F. Manolson, A. A. Khine, and O. D. Rotstein Interleukin-1 Increases Vacuolar-type H[IMAGE]-ATPase Activity in Murine Peritoneal Macrophages J. Biol. Chem., January 26, 1996; 271(4): 2005 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Johnson, S. Pizzo, M. Imber, and D. Adams Receptors for maleylated proteins regulate secretion of neutral proteases by murine macrophages Science, November 5, 1982; 218(4572): 574 - 576. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
